Biosimilar Drugs

Authors

  • LK Mela Dewi School of Pharmacy, Management and Science University (MSU), Malaysia

DOI:

https://doi.org/10.55175/cdk.v50i9.725

Keywords:

Biological medicine, biosimilar, drugs

Abstract

Biological medicines are medicines that are made or derived from a biological source and as such are complex molecules, with inherent variability in their structure. A biosimilar medicine is a biological medicine which is highly similar to another biological medicine already licensed for use. It is a biological medicine which has been shown not to have any clinically meaningful differences from the originator biological medicine in terms of quality, safety, and efficacy based on a comprehensive comparability exercise. Biologic products are widely used in treatment for neutropenia, cancer, inflammatory and autoimmune diseases, and enzyme or hormone deficiencies.

Obat-obatan biologis adalah obat-obatan yang dibuat atau berasal dari sumber biologis dan merupakan molekul kompleks, dengan variabilitas yang melekat pada strukturnya. Obat biosimilar adalah obat biologi yang sangat mirip dengan obat biologis lain yang sudah berlisensi untuk digunakan. Hal ini menunjukkan bahwa obat biologis terbukti tidak memiliki perbedaan bermakna secara klinis dari obat biologis pencetusnya dalam hal kualitas, keamanan, dan efikasi berdasarkan uji perbandingan secara komprehensif. Produk biologis banyak digunakan dalam pengobatan untuk neutropenia, kanker, penyakit inflamasi dan autoimun, dan enzim atau kekurangan hormon.

Downloads

Download data is not yet available.

References

Sekhon B, Saluja V. Biosimilars: An overview. Biosimilars 2011;1:1-11. doi: http://dx.doi.org/10.2147/BS.S16120

Boehncke WH, Radeke HH. Introduction: Definition and classification of biologics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2007. p. 1-2

Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization [Internet]. 2009 [cited 2018 May 5]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf .

What is a biosimilar medicine? Guide. National Health Service [Internet]. [cited 2018 May 13]. Available from: https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf.

Developing biosimilars in emerging markets: Regulatory and clinical considerations. Ppdi.com [Internet]. 2013 March. Available from: http://healthtrustpg.com/biosimilars/pdf/ppd.pdf

2016 Global Life Sciences Outlook. Moving forward with cautious optimism. Deloitte [Internet]. 2016 [cited 2018 May 13]. Available from: https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2016-life-sciences-outlook.pdf.

World Health Organization. WHO Expert Committee on biological standardization, sixty-sixth report [Internet]. 2015 [cited 2018 May 5]. Available from: http://www.who.int/biologicals/expert_committee/WHO_TRS_999_with_corrigenda_web.pdf?ua=1

European Medicines Agency. Guideline on similar biological medicinal products [Internet]. 2014 Oct 23. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: The science of extrapolation. Blood. 2014;124(22):3191-6. doi: 10.1182/blood-2014-06-583617.

Konangi S, Raviteja MN, Gupta NV. Comparison of global regulatory approvals for biosimilar products [Internet]. 2013. Available from: http://sphinxsai.com/2013/JulySept13/phPDF/PT=09(924-935)JS13.pdf

Health Canada. Guidance Document. Information and submission requirements for biosimilar biologic drugs [Internet]. 2016. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2016-eng.pdf

Johnson JA. Biologics and biosimilars: Background and key issues [Internet]. 2017 [cited 2018 May 5]. Available from: https://fas.org/sgp/crs/misc/R44620.pdf.

FDA. Biosimilar product regulatory review and approval [Internet]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM581309.pdf

Ahlstrom A, et al. Modeling federal cost savings from follow-on biologics. Avalere Health. 2007.

Blank T, Netzer T, Hildebrant W, Vogt-Eisele A, Kaszkin-Bettag M. Safety and toxicity of biosimilars—EU versus US regulation. GaBI Journal 2013;2(3):144-50.

The Challenges on Nomenclature-INN, biosimilars and biological qualifiers. GaBI Journal [Internet]. 2015 [cited 2018 May 21]. Available from: http://gabi-journal.net/the-challenges-of-nomenclature-inn-biosimilars-and-biological-qualifiers.html

WHO issues draft proposal for its biological qualifier. GaBI Journal [Internet]. 2015 [cited 2018 May 21]. Available from: http://gabionline.net/Policies-Legislation/WHO-issues-draft-proposal-for-its-biological-qualifier.

Grabowski H, Guha R, Salgado M. Biosimilar competition: Lessons from Europe. Nat Rev Drug Discov. 2014;13(2):99-100. doi: 10.1038/nrd4210.

Schwieterman P. A strategic review of biosimilars in oncology practice [Internet]. 2018 [cited 2018 May 21]. HOPA News Volume 15 Issue 1. Available from: http://www.hoparx.org/hopa-news/volume-15-issue-1-2018/a-strategic-review-of-biosimilars-in-oncology-practice

Badan Pusat Statistik. Persentase penduduk miskin September 2017 mencapai 10,12 persen [Internet]. 2018. Available from: https://www.bps.go.id/pressrelease/2018/01/02/1413/persentase-penduduk-miskin-september-2017-mencapai-10-12-persen.html)

Indonesia strides towards universal health care. The Lancet [Internet]. 2014. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62716-6/fulltext

The world health report 2010 – Health systems financing: The path to universal coverage. Geneva: World Health Organization [Internet]. 2010. Available from: http://www.who.int/whr/2010/whr10_en.pdf [accessed 2 June 2013]

Opportunities for biosimilars in emerging markets. GaBI Journal [Internet]. 2011 [cited 2018 May 21]. Available from: http://gabionline.net/Biosimilars/Research/Opportunities-for-biosimilars-in-emerging-markets.

BPOM. Peraturan Kepala Badan Pengawas Obat dan Makanan Nomor 16 Tahun 2015 tentang Tatalaksana dan Penilaian Proses Obat Pengembangan Baru. Jakarta, Indonesia; 2015.

Islam S, Chen Lu. Why the US biosimilars market will be slow to take off. Boston Consulting Group [Internet]. 2015. Available from: https://www.bcg.com/publications/2015/biopharmaceuticals-why-us-biosimilars-market-slow-take-off.aspx

Reiffen D, Ward MR. Generic drug industry dynamics. Review of economics and statistics, The MIT Press Journal 2005;87(1):37–49.

European Medicines Agency. Questions and answers on biosimilar medicines [Internet]. 2012. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/WC500020062.pdf

GaBI Online - Generics and biosimilars initiative. Interchangeability (switching and alternating) of biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International [Internet]. [cited 2015 May 13]. Available from: www.gabionline.net/Biosimilars/Research/Interchangeability-switching-andalternating-of-biosimilars

Blackstone, EA, Fuhr JP. The economic of biosimilars. 2013, American Health & Drug Benefit. Am Health Drug Benefits. 2013;6(8):469-78

Biosimilar Development. ProBioGen in biosimilar deal with bio farma Indonesia [Internet]. Available from: https://www.biosimilardevelopment.com/doc/probiogenin-biosimilar-deal-with-bio-farma-indonesia-0001

The Economist. Indonesia’s Kalbe launches biosimilar version of insulin [Internet]. 2017. Available from: http://www.eiu.com/industry/article/1405282924/indonesias-kalbe-launches-biosimilar-version-of-insulin/2017-03-31

GaBI Online: Cadila and Kalbe advancing biosimilar ambitions. Mol, Belgium: Pro Pharma Communications International [Internet]. [cited 2015 May 13]. Available from: http://www.gabionline.net/Biosimilars/General/Cadila-and-Kalbe-advancing-biosimilar-ambitions

GaBI Online: US$67 bilion worth of biosimilar patents expring before 2020. Mol, Belgium: Pro Pharma Communications International [Internet]. [cited 2015 May 13].Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

Downloads

Published

03-09-2018

How to Cite

Dewi, L. M. (2018). Biosimilar Drugs. Cermin Dunia Kedokteran, 45(9), 679–684. https://doi.org/10.55175/cdk.v50i9.725

Issue

Section

Articles